Discuss the role of biomanufacturing institutes like BRIC-NABI in advancing India's genetically modified crop research. What are the associated regulatory and ethical concerns?

India's agri-biotechnology push is being institutionalised through the Department of Biotechnology's Biotech Research and Innovation Council (BRIC), whose Mohali institute — formed by merging NABI and CIAB — is India's first dedicated biomanufacturing institute [2]. Such institutes can accelerate GM crop research, but their promise rests on a credible regulatory and ethical framework.

Role in advancing GM crop research

• Dedicated infrastructure: the first-of-its-kind "Green Forge" Complex at BRIC-NABI has been described by the Union Minister as a milestone in the GM crop revolution [1].
• Compressing breeding cycles: the "DBT SPEEDY SEEDS" National Speed Breeding Crop Facility shortens the generation time between transformation and field-ready lines [3].
• Translational capacity: the ₹42-crore BioFoundry, India's first such centre under DBT, links synthetic-biology design to scaled bio-manufacturing [4].
• Institutional consolidation: merging NABI and CIAB reduces duplication and pools agri-food and bioprocessing expertise [2].
• Public-sector counterweight: a strong public pipeline supports farm incomes and reduces dependence on proprietary foreign seed technology [2].

Regulatory concerns

• Approval runs through a layered chain — IBSC, RCGM and finally the GEAC under the MoEF&CC — making clearances slow and unpredictable [5].
• Regulator–promoter overlap: DBT both funds these institutes and co-chairs the GEAC, raising conflict-of-interest questions [5].
• Genome-edited plants under SDN-1/SDN-2 have been exempted from full biosafety appraisal, easing research but thinning oversight [7].
• Judicial scrutiny of GM mustard's environmental release leaves commercial-release policy unsettled; no autonomous biotechnology regulator yet exists.

Ethical concerns

• Biosafety and ecology: gene flow to wild relatives, effects on soil health and crop genetic diversity remain contested [6].
• Consumer autonomy: weak labelling limits informed choice.
• Farmer sovereignty: seed-replacement costs and IPR concentration threaten seed-saving traditions.
• Transparency: withheld biosafety dossiers erode public trust.

Institutes like BRIC-NABI are the supply side of India's food-security response; trust is the demand side. Pairing this infrastructure with a science-based, independent and transparent regulator — with open biosafety data and clear labelling — would let India harness gene technology while honouring the precautionary principle and Article 21's right to a safe environment.